Erythropoietin administration is associated with improved T-cell properties in patients with myelodysplastic syndromes
- PMID: 27870945
- DOI: 10.1016/j.leukres.2016.11.002
Erythropoietin administration is associated with improved T-cell properties in patients with myelodysplastic syndromes
Abstract
The immune system is impaired in myelodysplastic syndromes (MDS) and plays a role in the pathogenesis of the disease. Here we show effects of recombinant human erythropoietin (rHuEPO) on T cell (CD4+, CD8+ and CD4+CD25+) number and function in MDS patients. Healthy (20 subjects), MDS patients without rHuEPO treatment ('MDS', 13), and MDS patients treated with rHuEPO ('MDS+EPO', 17) were examined. CD4+ and CD8+ T cell numbers were reduced and increased respectively in MDS compared to healthy subjects. EPO treatment normalized these levels. CD4+CD25+ cell numbers, lower in MDS, were normalized in MDS+EPO. In vitro activation of CD4+ and CD8+ cells with phytohemagglutinin as measured by CD69 expression, demonstrated a 7.2 fold increase in CD4+ activation vs 13.6 fold for MDS and MDS+EPO respectively (p=0.004); and 10.2 fold (MDS) vs 18.6 fold (MDS+EPO, p<0.003) for CD8+ T cells. Expression of the co-stimulatory marker CD28, decreased in CD4+ and CD8+ T cells in MDS, was normalized in MDS+EPO CD4+ T cells. Subgroup analysis of milder disease (WHO RA and RARS) and more advanced disease revealed no difference in CD4+ and CD8+ T cell numbers. However, the activation of these cells in the RA/RARS subgroup was impaired in EPO-untreated and enhanced in EPO-treated MDS patients. Our data suggest that EPO treatment improves immune abnormalities in MDS and may depend on disease severity.
Keywords: Erythropoietin; Immune modulation; Lymphocytes; Myelodysplastic syndrome; T cells.
Copyright © 2016 Elsevier Ltd. All rights reserved.
Similar articles
-
Investigation for the presence of anti-erythropoietin antibodies in patients with myelodysplastic syndromes.Eur J Haematol. 2001 Jan;66(1):31-6. doi: 10.1034/j.1600-0609.2001.00336.x. Eur J Haematol. 2001. PMID: 11168505
-
Clinical significance of regulatory T cells in patients with myelodysplastic syndrome.Eur J Haematol. 2009 Mar;82(3):201-7. doi: 10.1111/j.1600-0609.2008.01182.x. Epub 2008 Nov 10. Eur J Haematol. 2009. PMID: 19018862
-
T-cell function, T-cell phenotype and its role in responsiveness to recombinant human erythropoietin in hemodialysis patients.Egypt J Immunol. 2010;17(2):67-80. Egypt J Immunol. 2010. PMID: 23082488
-
Advances in erythropoietic growth factor therapy for myelodysplastic syndromes.Expert Opin Biol Ther. 2006 Nov;6(11):1099-104. doi: 10.1517/14712598.6.11.1099. Expert Opin Biol Ther. 2006. PMID: 17049008 Review.
-
Immune alterations in untreated and treated myelodysplastic syndrome.Expert Opin Drug Saf. 2011 May;10(3):351-61. doi: 10.1517/14740338.2011.534456. Epub 2011 Mar 21. Expert Opin Drug Saf. 2011. PMID: 21417834 Review.
Cited by
-
[Research progress of bone marrow microenvironment abnormalities in myelodysplastic syndrome].Zhonghua Xue Ye Xue Za Zhi. 2017 Jul 14;38(7):643-646. doi: 10.3760/cma.j.issn.0253-2727.2017.07.022. Zhonghua Xue Ye Xue Za Zhi. 2017. PMID: 28810341 Free PMC article. Chinese. No abstract available.
-
Erythropoietin enhances Kupffer cell number and activity in the challenged liver.Sci Rep. 2017 Sep 4;7(1):10379. doi: 10.1038/s41598-017-11082-7. Sci Rep. 2017. PMID: 28871174 Free PMC article.
-
Erythropoietin and its derivatives: from tissue protection to immune regulation.Cell Death Dis. 2020 Feb 3;11(2):79. doi: 10.1038/s41419-020-2276-8. Cell Death Dis. 2020. PMID: 32015330 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous
